Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Johnson and Johnson
Baxter
Mallinckrodt
Boehringer Ingelheim

Last Updated: August 19, 2022

Investigational Drug Information for GTS-21


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug GTS-21?

GTS-21 is an investigational drug.

There have been 10 clinical trials for GTS-21. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2022.

The most common disease conditions in clinical trials are Schizophrenia, Tourette Syndrome, and Syndrome. The leading clinical trial sponsors are VA Office of Research and Development, University of Colorado, Denver, and CoMentis.

There are one hundred and two US patents protecting this investigational drug and nine hundred and fifty-two international patents.

Recent Clinical Trials for GTS-21
TitleSponsorPhase
Broad One Health Endectocide-based Malaria Intervention in Africa (BOHEMIA)UNITAIDPhase 3
Broad One Health Endectocide-based Malaria Intervention in Africa (BOHEMIA)Barcelona Institute for Global HealthPhase 3
Effects of GTS-21 on Smoking Behavior and Neurocognitive FunctionsNational Institute on Drug Abuse (NIDA)Phase 2

See all GTS-21 clinical trials

Clinical Trial Summary for GTS-21

Top disease conditions for GTS-21
Top clinical trial sponsors for GTS-21

See all GTS-21 clinical trials

US Patents for GTS-21

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GTS-21 See Plans and Pricing Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) See Plans and Pricing
GTS-21 See Plans and Pricing Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) See Plans and Pricing
GTS-21 See Plans and Pricing Crystalline(2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxym- ethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) See Plans and Pricing
GTS-21 See Plans and Pricing Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) See Plans and Pricing
GTS-21 See Plans and Pricing Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for GTS-21

Drugname Country Document Number Estimated Expiration Related US Patent
GTS-21 Australia AU2015210983 2034-01-30 See Plans and Pricing
GTS-21 Canada CA2934936 2034-01-30 See Plans and Pricing
GTS-21 China CN105992763 2034-01-30 See Plans and Pricing
GTS-21 European Patent Office EP3099678 2034-01-30 See Plans and Pricing
GTS-21 Spain ES2718239 2034-01-30 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Johnson and Johnson
Baxter
Mallinckrodt
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.